ReNeuron Group plc Share Purchases by Directors (6843W)

TIDMRENE

RNS Number : 6843W

ReNeuron Group plc

18 April 2019

 
 18 April 2019   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Share Purchases by Directors

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:

 
 Name          Title            Number         Total beneficial   Percentage 
                                 of Ordinary    interest in        of Company's 
                                 Shares         the Company's      Total Voting 
                                 purchased      Ordinary Shares    Rights 
 Professor 
  Sir Chris    Non-executive 
  Evans OBE     Director        10,000         254,605            0.802 
              ---------------  -------------  -----------------  -------------- 
 

ENDS

ENQUIRIES:

 
ReNeuron                                                                  [phone] 
Olav Hellebø , Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                                  [phone] 
Mark Court, Sophie Wills, Tilly Abraham 
 
Stifel Nicolaus Europe Limited                                            [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) 
Nplus1 Singer Advisory LLP                                                [phone] 
Aubrey Powell, Mark Taylor (Joint Broker) 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

Notification and public disclosure of transactions by persons discharging managerial

 
       Details of the person discharging managerial responsibilities 
   1    / person closely associated 
 a)    Name                              Professor Sir Chris Evans OBE 
      --------------------------------  --------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------- 
 a)    Position/status                   Non-Executive Director 
      --------------------------------  --------------------------------------- 
 b)    Initial notification              Initial notification 
        /Amendment 
      --------------------------------  --------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------- 
 a)    Name                              ReNeuron Group plc 
      --------------------------------  --------------------------------------- 
 b)    LEI                               2138003TU12CQ5TZO137 
      --------------------------------  --------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) 
        each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv) each place where transactions have been conducted 
      ------------------------------------------------------------------------- 
 a)    Description of                    Ordinary Shares 1p 
        the financial instrument,         RENE - GB00BF5G6K95 
        type of instrument 
        Identification 
        code 
      --------------------------------  --------------------------------------- 
 b)    Nature of the transaction         Purchase of ordinary shares 
      --------------------------------  --------------------------------------- 
 c)    Price(s) and volume(s)              Price(s)   Volume(s) 
                                            2.287      10,000 
                                                      ---------- 
      --------------------------------  --------------------------------------- 
 d)    Aggregated information            N/A 
      --------------------------------  --------------------------------------- 
 e)    Date of the transaction           18 April 2019 
      --------------------------------  --------------------------------------- 
 f)    Place of the transaction          London Stock Exchange AIM Market 
      --------------------------------  --------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHGGUBWCUPBGCR

(END) Dow Jones Newswires

April 18, 2019 10:40 ET (14:40 GMT)